The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
iwCLL 2021 | The state of CLL treatment in China
Shenmiao Yang, MD, Peking University Institute of Hematology, Peking University People’s Hospital, Peking, China, discusses recent findings from Chinese studies in the field of chronic lymphocytic leukemia (CLL). Dr Yang reports that an interest in fixed-duration therapies, partly driven by economic factors, has led to an increase in research of new drugs for the treatment of CLL, such as zanubrutinib. Additionally, research which reported a relatively high incidence of MYD88 and KMT2D mutations in Chinese patients with CLL may have implications for future treatment. Dr Yang emphasises the need to improve our understanding of the genetic mechanisms underpinning the ethnic differences in CLL. This interview was conducted during the 2021 virtual international workshop on CLL (iwCLL) congress.
Disclosures
Shenmiao Yang, MD, is an employee and stock option holder in Adaptive Biotechnologies, Inc.
